From insight to innovation

Probi^® was born out of a visionary research project at Lund University, Sweden, whose aim was to discover whether administering specific probiotics to critically ill patients could enhance therapeutic outcomes and improve their chances of recovery.

Based on the success of this project, which began in the mid-1980s, a patent application was filed for Lactiplantibacillus plantarum 299v (LP299V^®) today the company’s most studied bacterial strain. This research was the genesis of Probi's founding in 1991.

Listen to the story about saving lives, our foundation and how our Probi vision started.

Step by step

Probi entered the commercial market in 1994 with its launch in Sweden of ProViva, a fruit drink beverage based on the LP299V strain.

In the late 1990s and early 2000s, continued research and development paved the way for an international expansion, and the 2005 launch of Probi’s gut health concept, Probi Digestis^®.

Five years later, Probi’s immune health concept, Probi Defendum^®, was launched.

The first US agreement for dietary supplements was signed the following year, beginning a period of rapid expansion in the North American market.

In 2016, positive results in repeated clinical studies, evaluating the effects of probiotics on iron absorption, led to the launch of Probi FerroSorb^®.

With the acquisition of US company Nutraceutix in 2016, Probi became a vertically integrated probiotics company, with expertise in R&D, fermentation, production, quality, regulatory, marketing, and sales.

In 2018, Probi entered a new health area and launched Probi^® Osteo, a clinically documented probiotic concept, supporting bone health.

Since 2021, Probi has expanded through key partnerships and portfolio restructuring.

A collaboration with Blis Technologies in New Zealand granted exclusive US and Canadian distribution of BLIS K12™ and BLIS M18™, and in 2023, Probi partnered with UK-based Clasado Biosciences to develop synbiotics.

In 2024, Probi streamlined its offerings from five concepts to biotic solutions in nine key health areas. A strong focus has been put on mental health, supported by various studies on Lactiplantibacillus plantarum HEAL9®, and metabolic health – with Metabolic Health by Probi® unveiled in October 2024.

A key milestone in the last year was the unveiling of our bold new corporate brand identity, with vibrant green at its core. Alongside this, we introduced our updated vision — improving lives through the science of biotics — reinforcing our commitment to innovation and health.

In January 2025, Probi applied for delisting from Nasdaq Stockholm to become part of Symrise AG, a global supplier of fragrances, flavours, cosmetic ingredients, and nutrition solutions.